HC Wainwright Analysts Raise Earnings Estimates for OLMA

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Analysts at HC Wainwright upped their Q2 2025 earnings estimates for Olema Pharmaceuticals in a report released on Wednesday, May 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.37) per share for the quarter, up from their previous forecast of ($0.70). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.67) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($1.83) EPS, FY2028 earnings at ($1.42) EPS and FY2029 earnings at ($1.08) EPS.

Several other research analysts have also issued reports on the stock. The Goldman Sachs Group decreased their price target on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday. JPMorgan Chase & Co. decreased their target price on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, March 28th. Finally, Oppenheimer dropped their price target on Olema Pharmaceuticals from $25.00 to $22.00 and set an “outperform” rating on the stock in a research report on Wednesday.

Olema Pharmaceuticals Trading Up 4.2%

Shares of Olema Pharmaceuticals stock opened at $4.69 on Friday. Olema Pharmaceuticals has a 12 month low of $2.86 and a 12 month high of $16.62. The firm has a market capitalization of $320.61 million, a P/E ratio of -2.14 and a beta of 2.03. The business has a fifty day simple moving average of $4.29 and a two-hundred day simple moving average of $6.17.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, May 13th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13.

Institutional Trading of Olema Pharmaceuticals

Several institutional investors have recently bought and sold shares of OLMA. JPMorgan Chase & Co. lifted its stake in shares of Olema Pharmaceuticals by 658.7% in the third quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company’s stock worth $2,162,000 after buying an additional 157,171 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Olema Pharmaceuticals by 435.0% in the fourth quarter. Renaissance Technologies LLC now owns 157,300 shares of the company’s stock worth $917,000 after purchasing an additional 127,900 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of Olema Pharmaceuticals during the fourth quarter valued at $510,000. Hennion & Walsh Asset Management Inc. boosted its position in shares of Olema Pharmaceuticals by 80.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 212,246 shares of the company’s stock valued at $1,237,000 after buying an additional 94,651 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its position in shares of Olema Pharmaceuticals by 10.8% during the fourth quarter. Boothbay Fund Management LLC now owns 31,226 shares of the company’s stock valued at $182,000 after buying an additional 3,056 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.